3500 Participants Needed

Registry for Lupus

Recruiting at 25 trial locations
LN
Overseen ByLupus Nexus Director
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Lupus Research Alliance
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial focuses on gathering and storing detailed information about Systemic Lupus Erythematosus (SLE), a disease in which the immune system attacks the body's tissues, including Lupus Nephritis, which affects the kidneys. By collecting data and biological samples, researchers aim to support future studies that could lead to better treatments. Individuals diagnosed with SLE who can follow study directions are suitable candidates for this trial. As an unphased study, this trial allows patients to contribute to foundational research that could pave the way for future breakthroughs in SLE treatment.

Why are researchers excited about this trial?

Researchers are excited about the Lupus Landmark Study because it aims to create a comprehensive registry and biorepository that could revolutionize our understanding and treatment of lupus. Unlike current treatments that primarily focus on managing symptoms with immunosuppressants or anti-inflammatory drugs, this study seeks to gather extensive data and biological samples from patients over time. By doing so, it has the potential to uncover new biomarkers, identify novel therapeutic targets, and pave the way for more personalized and effective lupus therapies in the future. This approach is significant because it shifts the focus from just treating symptoms to understanding the disease at its core, which could lead to breakthroughs in treatment strategies.

Who Is on the Research Team?

SL

Sam Lim, MD, MPH

Principal Investigator

Emory University

AK

Arezou Khosroshahi, MD

Principal Investigator

Emory University

AK

Alfred Kim, MD, PhD

Principal Investigator

Washington University School of Medicine

Are You a Good Fit for This Trial?

Inclusion Criteria

Able to understand and comply with study procedures and voluntarily sign a written informed consent document
Systemic Lupus Erythematosus International Collaborating Clinic (SLICC) 2012 criteria; European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR) 2019 criteria; 1997 revised ACR criteria; or Lupus is present per clinical assessment.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Enrollment

Participants are enrolled into one of four cohorts: New Onset, Active Lupus Nephritis, Extra-Renal Lupus Flare, or Prevalent Cases

5 years

Data Collection

Collection of clinical data, biospecimens, and molecular data for future research on SLE

5 years

Follow-up

Participants are monitored for safety and effectiveness after data collection

up to 25 years

What Are the Treatments Tested in This Trial?

Find a Clinic Near You

Who Is Running the Clinical Trial?

Lupus Research Alliance

Lead Sponsor

Trials
6
Recruited
3,900+